General Hospital Psychiatry 2011-01-01

Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome.

Pang-Yen Liu, Pei-Chuan Wu, Chun-Yen Chen, Yi-Chyan Chen

Index: Gen. Hosp. Psychiatry 33(1) , 84.e5-7, (2011)

Full Text: HTML

Abstract

We present the case of a woman with paranoid schizophrenia who was receiving oral risperidone. She developed neuroleptic malignant syndrome (NMS) following the addition of depot fluphenazine for the treatment of refractory delusions. NMS subsided and psychotic features were controlled after both antipsychotics were discontinued and the patient was treated instead with olanzapine.Crown Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Related Compounds

  • Fluphenazine
  • Fluphenazine decan...

Related Articles:

Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.

2013-03-01

[J. Psychosoc. Nurs. Ment. Health Serv. 51(3) , 13-8, (2013)]

Latent inhibition in an insect: the role of aminergic signaling.

2012-01-01

[Learn. Mem. 19(12) , 593-7, (2012)]

[Copper intoxication decreases lifespan and induces neurologic alterations in Drosophila melanogaster].

2013-03-01

[Invest. Clin. 54(1) , 47-57, (2013)]

Perphenazine suspension: a new, old treatment, side effects and continuous use.

2012-09-01

[Psychiatr. Q. 83(3) , 335-41, (2012)]

Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.

2012-01-01

[Med. Sci. Monit. 18(1) , CR44-49, (2012)]

More Articles...